Drug Approval | July 26, 2023
Eugia Pharma receives USFDA approval for Plerixafor Injection
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
The product is expected to be launched in June 2023
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Subscribe To Our Newsletter & Stay Updated
